PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design, is delighted to announce that it has been awarded $2 million by the United States Biomedical Advanced Research and Development Authority (BARDA) as one of the winners of the Concept Stage of BARDA’s Patch Forward Prize for its seasonal …
COPENHAGEN, Denmark, and PARIS, France, January 13, 2025 — Heimdal, a top European cybersecurity company, is teaming up with Watsoft, a French IT distributor focused on Managed Service Providers (MSPs). This partnership will help MSPs in France deal with today’s growing cybersecurity challenges by simplifying how they manage security and …
Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, …
Arctic Bioscience is now funded through a NOK 30 million loan facility. Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. Psoriasis drug candidate HRO350 on track for 12 months readout end of Q1. Reference is made to the stock exchange …
Stock Exchange Release 13.01.2025 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class FSKRS Amount 2000 Average price/share 14.5861 EUR Highest price/share 14.6200 EUR Lowest price/share 14.5000 EUR Total price 29,172.20 EUR The …
ALEXANDRIA GROUP OYJ NOTIFICATION 13.01.2025 at 18:30 EET ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class ALEX Amount 200 Average price/share 8,8500 EUR Highest price/share 8,8500 EUR Lowest price/share 8,8500 EUR Total price 1 …
Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients …
STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™ in Europe. The Company has signed a non-binding …
THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT …
FIDELITY CHINA SPECIAL SITUATIONS PLC (the 'Company') TRANSACTION IN OWN SHARES The Board of the Company announces that it has repurchased for cancellation. Number of shares repurchased: 300,000 Date of transaction: 13 January 2025 Average share price paid per share (GBp): 213.840 Lowest share price paid per share (GBp): …
